Text Size

Identigene STD Test Collection Kit Validation Study

This study is currently recruiting participants.
Verified May 2013 by Identigene
Sponsor:
Collaborator:
CRI Lifetree Clinical Research
Information provided by (Responsible Party):
Identigene
ClinicalTrials.gov Identifier:
NCT01471392
First received: November 10, 2011
Last updated: May 31, 2013
Last verified: May 2013
History of Changes
  Purpose

The overall goal of the present study is to provide evidence of concordant test results using the Identigene STD Test Collection Kit for self-collection and transport of specimens to a qualified testing laboratory. It is expected that this method will aid in detection of CT and NG and that offering a method of self-collection of a male urine or female vaginal swab specimen will encourage testing for CT and NG and improve the overall detection of reporting of these STDs by allowing persons who suspect they have the infection to be tested in a discrete and confidential manner. The reporting of CT and NG are underestimated and many subjects will not visit a clinic or obtain treatment if gone undetected. Thus, allowing a self-collection kit that is more convenient may result in improved reporting, identification of CT and NG positive individuals, and subsequent treatment to help prevent the spread of these diseases.

The purpose of this study is to demonstrate that the Identigene STD Test Collection Kit and labeled instructions for use instructions provide test results that are concordant (at least 95% or better) with test results obtained using the Gen-Probe APTIMA Combo 2 specimen collection and transport methods performed under the supervision of a healthcare provider. The laboratory technology and test method used for the IDTG-100.


Condition Intervention Phase
Infection
 Device: STD Diagnostic Kit (Identigene)
 Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Diagnostic
Official Title: Identigene STD Test Collection Kit Validation Study

Further study details as provided by Identigene:

Primary Outcome Measures:
  • Effectiveness of the Identigene STD Test Collection Kit in comparison to the Gen-Probe Aptima Combo 2 Assay [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Demonstration of the effectiveness of the Identigene STD Test Collection Kit based on the percentage of concordant positive and negative results as compared to the Gen-Probe APTIMA Combo 2 assay conducted at an STD clinic.


Secondary Outcome Measures:
  • Evaluation of the Identigene STD Test Collection Kit instructions. [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    To determine if the instructions of the Identigene STD Test Collection Kit are adequate for proper specimen self-collection and specimen submission to the laboratory for processing.


Estimated Enrollment: 3000
Study Start Date: November 2011
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Identigene STD Test Kit Arm
Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
 Device: STD Diagnostic Kit (Identigene)
The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
Other Name: Identigene STD Test Collection Kit

Detailed Description:

This is a multicenter study involving asymptomatic and symptomatic subjects who are at risk or suspect possible exposure to CT and/or NG. Approximately five (5) clinics will participate in the study. The clinics selected will be located in diverse geographical regions in order to represent populations with both high and low incidences of CT and NG and to represent different extremes in climate. The initial phase of the study enrolled approximately 500 qualifying subjects. An interim analysis was performed to determine whether changes in the study protocol were necessary. Changes to the protocol were identified and are incorporated in this amendment (amendment 4) of the study protocol. Specifically, males in the study will still collect urine specimens whereas women will now self-collect a vaginal swab specimen. Study subjects will only undergo one clinic visit rather than two as indicated in prior versions of the study protocol. The proposed study phases outlined in this amendment of the study protocol will include at least 200 qualifying subjects with intermittent suspension of the study to allow data analysis. The present study will continue until 200 CT positive test results (approximately 100 male and 100 female) are obtained. Of these 200 positive results, approximately 50% will be from symptomatic subjects and 50% from asymptomatic subjects. Since the positivity rate is presumably lower for asymptomatic subjects, the ration of symptomatic to asymptomatic subject enrollment for each study phase will be determined by the sponsor and will be made known in writing to each study site.

It is expected that approximately 3,000 subjects will be required to meet the overall study objectives. It is anticipated that the total number of subjects enrolled for testing throughout the study will yield approximately 30 positive NG samples (approximately 15 males and 15 females) with no requirement for a specific ratio of symptomatic to asymptomatic subjects. Subjects who are at high risk of exposure or suspect exposure to CT or NG, but are not currently being treated, will be recruited for enrollment.

  Eligibility

Ages Eligible for Study:   14 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Symptomatic females or males, age 14 or older, who present at a participating clinic with symptoms consistent with Chlamydia trachomatis or Neisseria gonorrhoeae infection, or
  2. Asymptomatic females or males, age 14 or older, who present at a participating clinic and who suspect that they have CT and/or NG, or are considered at high risk of exposure (e.g., sexual partner that tests positive for CT, or NG, multiple sexual partners, ect.),
  3. Individuals who are capable of understanding and agree to fulfill the requirements of the protocol.
  4. Individuals who have signed the IRB approved informed consent form.

Exclusion Criteria:

  1. Individuals with physical or mental inability that, in the opinion of the investigator can interfere with the subject's ability to follow the Identigene STD Test Collection Kit instructions,
  2. Individuals who are currently being treated for CT or NG or who are currently receiving antibiotics or have received antibiotics within the last 28 days, and
  3. Individuals who are suspected of being victims of sexual abuse or nonconsensual contact of a sexual nature within the previous 6 months or who are part of an ongoing sexual abuse legal case.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01471392

Contacts
Contact: Michael Smith 801-859-7818 mikes@lifetreeresearch.com

Locations
United States, Maryland
John Hopkins University Recruiting
Baltimore, Maryland, United States
Contact: Charlotte Gaydos, MD     410-614-0932     cgaydos@jhmi.edu    
Contact: Patricia Buist     410-614-0932     cgaydos@jhmi.edu    
Principal Investigator: Charlotte Gaydos, MD            
Sponsors and Collaborators
Identigene
CRI Lifetree Clinical Research
Investigators
Study Director: Mike Smith Lifetree Clinical Research
Study Chair: Lars Mouritsen, PhD Identigene
  More Information

Additional Information:
CDC Information on Chlamydia  This link exits the ClinicalTrials.gov site
CDC Information on Gonorrhea  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Identigene
ClinicalTrials.gov Identifier: NCT01471392     History of Changes
Other Study ID Numbers: IDTG-100
Study First Received: November 10, 2011
Last Updated: May 31, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Identigene:
Identigene
STD Test
Chlamydia
 Gonorrhoeae
APTIMA
Sexually Transmitted Disease

ClinicalTrials.gov processed this record on June 18, 2013